TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00655499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg
Study: NCT02442375

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard dose prescription
Description: * standard elective dose~* no intermediate dose-level~* visual interpretation of FDG-PET-scan
Study: NCT00655499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: 180 mg/kg

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Chromogenic in situ hybridization

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Study: NCT04607941

Intervention type: OTHER
Intervention: Questionnaires
Description: Self-administered questionnaires

Intervention type: OTHER
Intervention: Phone interviews
Description: A small amount of subjects will be selected at random for phone interviews.

Intervention type: OTHER
Intervention: Phone interviews
Description: A small amount of subjects will be selected at random for phone interviews.

Intervention type: OTHER
Intervention: Phone interviews
Description: A small amount of subjects will be selected at random for phone interviews.
Study: NCT03809091

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole genome sequencing
Description: Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
Study: NCT04371640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 1 MG/ML
Description: Oral solution
Study: NCT02442375

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET guided gradient dose prescription
Description: * de-escalation of elective dose~* intermediate dose-level~* standardized methods to evaluate FDG-PET-scan
Study: NCT04371640

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study: NCT00644904

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D3
Study: NCT01946672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower-limb drainage isotopic intraoperative detection
Description: A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
Study: NCT02456636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fee-for-Service Model (FFS, In clinic individual visits)
Description: To be performed by participant's doctor or other healthcare professional in their doctor's office.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Centered Medical Home (PCMH, In clinic group visits)
Description: To be performed by a registered dietitian, a nurse or other healthcare professional in their local setting.
Study: NCT00655499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Study: NCT03140670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUCAPARIB
Description: Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
Study: NCT00028548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R(+)XK469
Study: NCT03965949

Intervention type: DRUG
Intervention: Hormone Replacement cycle 1
Description: Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
Study: NCT02456636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease Management (DM, Phone group visits)
Description: To be performed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling via telephone.
Study: NCT02281955

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or alternative)
Description: Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment for surgical evaluation
Description: Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
Study: NCT02427568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDMA (125 mg)
Description: Two sessions of MDMA (with therapy) lasting six to eight hours, scheduled two to four weeks apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sessions of placebo (with therapy) lasting six to eight hours, scheduled two to four weeks apart.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy
Study: NCT03965949

Intervention type: DRUG
Intervention: Hormone Replacement cycle 1
Description: Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)

Intervention type: DRUG
Intervention: Hormone Replacement cycle 2
Description: Hormone Replacement cycle with GnRHa suppression

Intervention type: DRUG
Intervention: Hormone Replacement cycle 2
Description: Hormone Replacement cycle with GnRHa suppression
Study: NCT00070486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: given IV
Study: NCT04603781

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CBD Isolate
Description: 300 mg. daily dose of CBD Isolate Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Full Spectrum CBD Oil
Description: 300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broad-Spectrum CBD Oil
Description: 300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: MCT Oil with mint flavoring
Study: NCT02417116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tear supplement
Description: Application as required to improve comfort

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tear supplement 2
Description: Application as required to improve comfort

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 nutrition supplement
Description: Taken each day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye bag
Description: Applied following microwave heating to closed eyelids for 5 minutes each day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Application as required to improve comfort
Study: NCT00070486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zileuton
Description: given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zileuton
Description: given PO
Study: NCT01510015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: variable dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: variable dose
Study: NCT03122821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Transcranial direct stimulation+Mental Imagery
Description: The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Direct Stimulation +Mental Imagery
Description: The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks
Study: NCT05186103

Intervention type: OTHER
Intervention: observation
Description: The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).

Intervention type: OTHER
Intervention: observation
Description: The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).

Intervention type: OTHER
Intervention: observation
Description: The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
Study: NCT00031655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSCT
Study: NCT03351400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells administered to participants
Description: Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
Study: NCT00031655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO
Study: NCT02867982

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subcrestal implant placement
Description: Dental implants placed 2 mm below the alveolar ridge

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Paracrestal implant placement
Description: Dental implants placed flush to the alveolar ridge

Intervention type: DRUG
Group type: OTHER
Intervention: prophylactic antibiotics
Description: amoxicillin was used before and after implant surgery for prophylactic reasons

Intervention type: DRUG
Group type: OTHER
Intervention: prophylactic antibiotics
Description: amoxicillin was used before and after implant surgery for prophylactic reasons

Intervention type: DEVICE
Group type: OTHER
Intervention: dental implant
Description: dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge

Intervention type: DEVICE
Group type: OTHER
Intervention: dental implant
Description: dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
Study: NCT00031655

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSCT
Study: NCT02867982

Intervention type: RADIATION
Group type: OTHER
Intervention: x-ray examination
Description: radiographies were taken before treatment and at different time point during the follow-up period
Study: NCT01215617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Interval training
Description: Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Standard medical treatment
Study: NCT00635739

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: powdered, 46g supplement dissolved in fluids, twice daily
Study: NCT01259570

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Skimmilk enriched with VD encapsulated in CM

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: VD will be dissolved in milkfat and homogenized into skimmilk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: group 3
Description: 3% fat milk wherein the VD will be in CM

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 4
Description: Placebo: un-enriched skimmilk.
Study: NCT02704052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Real time enoxaparin dose adjustment
Description: Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard enoxaparin dose
Description: Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
Study: NCT03002194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutometer
Description: Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photographs
Description: Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
Study: NCT03450642

Intervention type: OTHER
Intervention: Observational
Description: Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
Study: NCT04559698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-affirmative CBT training
Description: Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-affirmative CBT training
Description: Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.
Study: NCT01278030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D echo-guided LV lead placement
Description: Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
Study: NCT04284878

Intervention type: GENETIC
Intervention: PCR-RFLP
Description: PCR-Restriction fragment length polymorphism
Study: NCT00635739

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo
Description: powdered, 46g supplement dissolved in fluids, twice daily
Study: NCT04610892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer
Study: NCT04627181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycobalamin
Description: Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycobalamin
Description: Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
Study: NCT03989973

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastroscopy
Description: Gastroscopy
Study: NCT02146703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, and S-1
Description: Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14
Study: NCT00445939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 160 mg at Week 0, 80 mg at Week 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 80 mg at Week 0, 40 mg at Week 2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo at Week 0 and Week 2
Study: NCT02415751

Intervention type: BEHAVIORAL
Intervention: heart failure self-care education
Description: It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.